Evidence map›Paper›PMID 36652163›Full record

ArticleJournal of racial and ethnic health disparities2024

Disparities in SARS-CoV-2 Infection by Race, Ethnicity, Language, and Social Vulnerability: Evidence from a Citywide Seroprevalence Study in Massachusetts, USA.

Wilfredo R Matias, Isabel R Fulcher, Sara M Sauer, Cody P Nolan, Yodeline Guillaume, Jack Zhu, Francisco J Molano, Elizabeth Uceta, Shannon Collins, Damien M Slater and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of racial and ethnic health disparities, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Wilfredo R Matias *Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit St, BUL-130, Boston, MA, 02114, USA. wmatias@bwh.harvard.edu.ORCID http://orcid.org/0000-0002-5371-1354
Isabel R Fulcher *Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
Sara M SauerDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
Cody P NolanDepartment of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Yodeline GuillaumeCenter for Global Health, Massachusetts General Hospital, Boston, MA, USA.
Jack ZhuCenter for Global Health, Massachusetts General Hospital, Boston, MA, USA.
Francisco J MolanoCenter for Global Health, Massachusetts General Hospital, Boston, MA, USA.
Elizabeth UcetaCenter for Global Health, Massachusetts General Hospital, Boston, MA, USA.
Shannon CollinsCenter for Global Health, Massachusetts General Hospital, Boston, MA, USA.
Damien M SlaterDivision of Infectious Diseases, Massachusetts General Hospital, 55 Fruit St, BUL-130, Boston, MA, 02114, USA.
Vanessa M SánchezDivision of Infectious Diseases, Massachusetts General Hospital, 55 Fruit St, BUL-130, Boston, MA, 02114, USA.
Serina MoheedDivision of Infectious Diseases, Massachusetts General Hospital, 55 Fruit St, BUL-130, Boston, MA, 02114, USA.
Jason B HarrisDivision of Infectious Diseases, Massachusetts General Hospital, 55 Fruit St, BUL-130, Boston, MA, 02114, USA.
Richelle C CharlesDivision of Infectious Diseases, Massachusetts General Hospital, 55 Fruit St, BUL-130, Boston, MA, 02114, USA.
Ryan M PaxtonHolyoke Board of Health, Holyoke, MA, USA.
Sean F GonsalvesHolyoke Board of Health, Holyoke, MA, USA.
Molly F FrankeDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
Louise C IversDivision of Infectious Diseases, Massachusetts General Hospital, 55 Fruit St, BUL-130, Boston, MA, 02114, USA.
Massachusetts General Hospital · USHarvard University · USBrigham and Women's Hospital · USHolyoke Community College · US

Funding

PROGRAM FOR AIDS CLINICAL RESEARCH TRAINING (PACRT)T32AI007433 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MARK J SIEDNER · 1992 to 2026
$11.4M
ACL HHS U01CK000490CDC HHS U01CK000490NCEZID CDC HHS U01 CK000490NIAID NIH HHS T32 AI007433
6 · The paper itself

Abstract

objectivesUncovering and addressing disparities in infectious disease outbreaks require a rapid, methodical understanding of local epidemiology. We conducted a seroprevalence study of SARS-CoV-2 infection in Holyoke, Massachusetts, a majority Hispanic city with high levels of socio-economic disadvantage to estimate seroprevalence and identify disparities in SARS-CoV-2 infection.

methodsWe invited 2000 randomly sampled households between 11/5/2020 and 12/31/2020 to complete questionnaires and provide dried blood spots for SARS-CoV-2 antibody testing. We calculated seroprevalence based on the presence of IgG antibodies using a weighted Bayesian procedure that incorporated uncertainty in antibody test sensitivity and specificity and accounted for household clustering.

resultsTwo hundred eighty households including 472 individuals were enrolled. Three hundred twenty-eight individuals underwent antibody testing. Citywide seroprevalence of SARS-CoV-2 IgG was 13.1% (95% CI 6.9-22.3) compared to 9.8% of the population infected based on publicly reported cases. Seroprevalence was 16.1% (95% CI 6.2-31.8) among Hispanic individuals compared to 9.4% (95% CI 4.6-16.4) among non-Hispanic white individuals. Seroprevalence was higher among Spanish-speaking households (21.9%; 95% CI 8.3-43.9) compared to English-speaking households (10.2%; 95% CI 5.2-18.0) and among individuals in high social vulnerability index (SVI) areas based on the CDC SVI (14.4%; 95% CI 7.1-25.5) compared to low SVI areas (8.2%; 95% CI 3.1-16.9).

conclusionsThe SARS-CoV-2 IgG seroprevalence in a city with high levels of social vulnerability was 13.1% during the pre-vaccination period of the COVID-19 pandemic. Hispanic individuals and individuals in communities characterized by high SVI were at the highest risk of infection. Public health interventions should be designed to ensure that individuals in high social vulnerability communities have access to the tools to combat COVID-19.

Indexed as

COVID-19EthnicityAntibodies, ViralBayes TheoremHumansImmunoglobulin GLanguageMassachusettsPandemicsSARS-CoV-2Seroepidemiologic StudiesSocial VulnerabilityAntibodies, ViralImmunoglobulin GAntibodiesCOVID-19DisparitiesSARS-CoV-2SeroprevalenceSerosurvey

Identifiers

PMID36652163
PMCPMC9847437
OpenAlexW4317213583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.